Here’s what you should know.
1. The National French Registry analyzed Cellvizio in a post-market observational study.
2. Researchers measured Cellvizio’s effectiveness against 399 prospective CLE procedures between September 2013 and February 2015 at 12 participating centers.
3. Cellvizio’s overall imaging quality was positive in 83 percent of cases and negative in 1 percent of cases.
4. Cellvizio’s histological diagnostic findings and correlation with histology was equal or greater than 0.90 concerning Barrett’s Esophagus detection and follow-up, biliary strictures characterization and pancreatic cysts characterization.
Mauna Kea Technologies CEO Sacha Loiseau, PhD, said, “The results from this large, comprehensive and independent national registry confirm the expansion and ease of use of our technology, the quick adoption and learning curve, and the safety and the strong correlation of the Cellvizio procedure with histological and pathological findings.”
More articles on gastroenterology:
Takeda expands gastroenterology efforts: Announces collaboration with NuBiyota: 3 insights
Valeant shares plummet 23% in March; Takeda continues expanding in GI space & more — 6 GI company key notes
GI leader to know: Dr. Truc Trinh of Gastroenterology Center of Northern Virginia
